Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Gross Paul Edward
 2. Date of Event Requiring Statement (Month/Day/Year)
02/01/2019		 3. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [CLVS]
(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

BOULDER, CO 80301		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2,345
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 01/25/2026 Common Stock 60,000 $ 22.99 D  
Stock Option (right to buy)   (2) 03/27/2027 Common Stock 15,000 $ 68.31 D  
Stock Option (right to buy)   (3) 03/01/2028 Common Stock 9,000 $ 58.43 D  
Restricted Stock Units   (4) 03/27/2027 Common Stock 4,219 $ (5) D  
Restricted Stock Units   (6) 03/01/2028 Common Stock 9,000 $ (5) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gross Paul Edward
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER, CO 80301		       See Remarks  

Signatures

/s/ Paul Gross 02/01/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option vested as to 25% of the shares on January 25, 2017, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
(2) The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
(3) The option vests as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date.
(4) The Restricted Stock Units vested as to 25% of the units on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
(5) Each Restricted Stock Unit represents the right to receive one share of Common Stock.
(6) The Restricted Stock Units vest as to 25% of the units on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
 
Remarks:
Executive Vice President, General Counsel and Chief Compliance Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.